



Millions of hip fracture patients face 1 challenge.

Death within the 1st year post surgery!





Transforming Orthopedic Rehabilitation

by

Monitoring progress remotely 24/7
Enabling a personalized care pathway
Empowering the patient

PROBLEM


Millions of hip fracture patients face 1 challenge: Death within the 1st year post surgery.



2 out of 5 hip fracture patients die

within the 1st year

are submitted to care homes permanently



Tidal wave of hip fractures due to demographic aging

~2 Million today



Identify patients at risk

Detect complications

Monitor aftercare progress





SOLUTION

Our data-driven biosensor platform enables successful rehabilitation on a large scale.

Implanted biosensor enables



PATIENT / FAMILY

Lower mortality rate

Return home early & safe mobilization

Peace of mind & patient empowered via progress visibility

HOSPITALS / DRs

Reduction hospital length of stay (-30%)

Remote care / inperson follow-ups only if needed

Targeted aftercare measures to increase rehab success rate

Lower post-surgery complication rate

HEALTH ECONOMY

Reduction of longterm care rate (-30%)

Fewer complications

Reduction hospital length of stay (-30%)

Lower aftercare cost









Our biosensor enables real-time aftercare management compatible with current implants.





88% of US healthcare providers are investing in remote patient monitoring solutions.





TAM
Musculoskeletal
conditions
(Worldwide)



SAM
Musculoskeletal
conditions
(US only)



Launch market - SOM
Hip fracture
(US only, single hip nail)

COMPETITION

No competitor solves for fracture loading & wearing compliance – our solution covers both.



	BIO))S	mcroberts	canary	moticon	GARMIN
Wearing Compliance	100%	low	100%	low	medium
Data continuity				*	~
Data quality	high	medium	high	medium	low
Mobility Data		~		~	~
Load Data					
Temperature Data	/		*	*	
Sensor position	Нір	On skin	Knee	Insole	Wrist

Partnering with a market leader will accelerate market penetration in the US and worldwide.



MARKET ENTRY

Fast market entry -FDA regulatory approval currently favorable over MDR

Reimbursement codes for remote data monitoring available today



DISTRIBUTION

Partner with Stryker or J&J for distribution to

Accelerate market adoption and scale-up of sales world-wide

Both hold ~35% market share in the US



stryker

BEACH HEAD MARKET

Leverage longstanding personal relationships with AO foundation surgeon network to establish lighthouse hospitals.



LOI issued by market leader. 1st sale of 16 units.



MVP & IP & SALES

Bootstrapped (incl. grants) by founders up to MVP

Sustainable Tech
Advantage full product
family patent pending,
freedom to operate
(FTO) in place

1st sale of 16 units for fracture boots to be used in a clinical study

DISTRIBUTION

Successfully completed technology due diligence by market leader

Letter of intent in place





PRIZES & FUNDING

Part of 2024 "Swiss National Startup team" (Venture Leaders MedTech)

Best AgeTech 2023 and Tech Startup 2024 awards

Lead and co-investors for seed round secured





FDA submission in 2026. US market entry in 2027. Exit via acquisition post 2028.






US market revenue projections > USD70M in 2030. Staggered sensor rollout as of 2027.



US Market only

US Market Roll-out 2027 HIP 2028 SPINE 2029 ACL





We have taken active implants from idea to market implementation successfully before.





MARKUS WINDOLF, PhD CEO & Founder

Successfully developed & brought to market active implanted biosensor.





PATRICK STEPANEK, PhD COO & Founder

20 years of biz leadership and start-up experience vistaprint in the EU and USA spinenuances (nu)



Lead SW engineer for active implanted biosensor technology.





ROBERT FRIGG, PROF. DR.

Former CTO of DePuy Synthes, today J&J.





BENEDIKT BRAUN, PROF. DR. MBA

Mobility tracking specialist and reconstructive surgeon.





BERND GRIMM, PhD

World renowned expert in human movement sciences.





MICHAEL SCHÜTZ, PROF. DR.

Globally recognized orthopedic surgeon and KOL orthopedic rehabilitation.





CURRENT STATUS

MVP hip sensor including age-group testing.



Hip Sensor prototype (benchtested, proof of concept)





Real-life system validation with age-group and sensor-integrated shoes completed









Sensor-integrated orthopedic boots developed and shipped to Australia for clinical trial



Spine sensor prototype developed and tested

\$2M pre-seed funding round



Seeking \$2M pre-seed funding for medical device development to reach "Design Freeze" Milestone

- lead & co-investors secured
- \$1M committed

Seed round of \$4M in 2026 to obtain FDA approval









Empowering patients with real-time rehabilitation progress data.



Dr. Patrick Stepanek, COO BIOS Medical AG

<u>markus.windolf@biosmedical.care</u> <u>www.biosmedical.care</u>



www.biosmedical.care